Journal article

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia

Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Sally Beard, Ping Cannon, Roxanne Hastie, Tuong V Nguyen, Natalie K Binder, Stephen Tong, Natalie J Hannan



INTRODUCTION: The discovery of new treatments that prevent or treat preeclampsia would be a major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are secreted in excess from the placenta, causing hypertension, endothelial dysfunction, and multiorgan injury. We recently identified metformin and esomeprazole as potential treatments for preeclampsia. Both reduce placental and endothelial secretion of sFlt-1 and soluble endoglin, and reduce endothelial dysfunction. OBJECTIVES: We set out to assess whether combining metformin and esomeprazole would additively reduce sFlt-1 and soluble endoglin secretion and reduce endothelial dysfunction (ve..

View full abstract


Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC

Funding Acknowledgements

This study was funded by the Norman Beischer Medical Research Foundation and a grant from the National Health and Medical Research Council of Australia (NHMRC #1101871). The NHMRC also provided salary support (#1050765 to ST #1062418 to TKL). NJH salary was supported by a University of Melbourne CR Roper Fellowship. The funders had no role in study design, data collection, analysis or decision to publish.